FGEN Earnings

FGEN reported its FY2025Q3 earnings on 2025-11-10, showcasing a revenue of 1.00M against an estimate of 2.00M, resulting in a -34.39% surprise. The EPS was -1.61, surpassing the expected -4.01 by 59.85% . The stock experienced a -9.64% price change on the earnings day and a -21% change over the next five days, reflecting market reactions to the results.

Following FGEN's FY2025Q3 earnings announcement on 2025-11-10, the stock price moved by -9.64% on the day of the release. Over the subsequent five days, it saw a -21.00% change. Historically, FGEN's stock price tends to shift by an average of +21.08% in the 10 days leading up to earnings and -6.70% in the 10 days following, providing insight into potential market.

For 2025/Q3, analysts estimate FGEN’s annual revenue to reach 2.00M, while the EPS is projected at -4.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Downward by -2.17% and EPS estimates Revise Upward by 0.3% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between FGEN's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Downward by -2.17%, while EPS estimates moved Revise Upward by 0.3% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, FGEN's stock price typically moves by +21.08% in the 10 days before its earnings and -6.70% in the 10 days after. For the upcoming 2025/Q3 earnings, analysts expect an EPS of -4.00 and revenue of 2.00M.

The earnings call reveals a positive financial performance with increased revenue and reduced expenses. However, uncertainties remain, such as the thrombotic risk in the roxadustat trial and the need for additional capital for Phase III trials. While the company plans to extend its cash runway through strategic sales, the potential impact on operational capacity and flexibility creates a balanced outlook. The raised revenue guidance and cash runway extension are positive, but the Q&A highlights risks and uncertainties that temper overall sentiment, resulting in a neutral prediction.